ALPACA (J3L-MC-EZEB)
LY3473329 Lp(a) siRNA (subcutane) for secondary MACE prevention in patients with elevated Lp(a)
- Stage
- klaar
- Medicine
- LY3819469 Lp(a) siRNA (subcutaan)
- Population
- ASCVD
- Phase
- II
- First Patient In
- 9 February 2023
- Last Patient In
- 17 April 2023
- Last Patient Last Visit
- 7 October 2024
Study Director
dr. M.F.L. Meijs
Cardioloog
Office Contact
